PARK INNOVARE

News

Six candidates to join the Swiss BIC of CERN Technologies incubation program

The Swiss Business Incubation Centre (BIC) of CERN Technologies entrepreneurship program is going to Phase II. Out of nearly 20 candidates from Switzerland...

More details More details

PARK INNOVAARE SECURES THE FINANCING OF ITS NEW CAMPUS

PARK INNOVAARE is an innovation park next to the Paul Scherrer Institute PSI and its unique complex of large research facilities. It offers technology-driven...

More details

4. ordentliche Generalversammlung der innovAARE AG

(This information is only available in German) Der PARK INNOVAARE markiert einen weiteren wichtigen Meilenstein in seiner Entwicklung: Die Finanzierung...

More details

Dr. Fabia Gozzo: an exceptional, creative, inventive, and innovative woman and entrepreneur

In a couple of weeks, London will welcome some of the world’s most innovative women from all sectors and backgrounds. The 21st Global Women Inventors,...

More details

Novel Accelerators for Electron Diffraction workshop at PARK INNOVAARE

Understanding how matter creates life requires observing living cells with atomic detail. There are many ways to do so, but one possibility has been gaining...

More details

WE ARE HIRING!

PARK INNIVAARE is an innovation park next to the Paul Scherrer Institute PSI. It offers academic spin-offs, innovative start-ups, SMEs and big companies,...

More details

A platform to discuss high-level topics with the pharmaceutical industry

Novartis (Switzerland) and Alphora (Canada) joined the case study program conducted as part of the Second Annual Spring Pharmaceutical Synchrotron X-Ray...

More details

BIC of CERN Technologies calls for innovative ideas leveraging accelerator technologies

As of today, start-ups and spin-offs, as well as small high-tech companies, younger than two years, can apply to become the next Business Incubation Centre...

More details

InterAx partners with Lundbeck to identify better pharmaceutical compounds

InterAx Biotech AG, a spin-off of the Paul Scherrer Institute PSI and ETH Zurich, based at PARK INNOVAARE, is building a proprietary systems biology platform...

More details

Excelsus invites pharma companies to explore for free the possibilities of synchrotron X-ray powder diffraction

The second annual Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction (SPS-XRPD-2) Workshop, organized together with the 16th Pharmaceutical Powder...

More details

InterAx raises CHF 3 Mio for the commercialization of its systems biology platform

InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by...

More details

Two well-known techniques + new application field = breakthrough of the year

This fall, Dr. Tim Grüne from the Paul Scherrer Institute (PSI) together with Crystallise! AG published the results of their joint project, presenting...

More details
1 2 3 4 5 6 7 8